FGFR2 and cholangiocarcinoma: In the final analysis of FIGHT-202, continued benefit of pemigatinib in patients with previously treated advanced or metastatic CCA with FGFR2 rearrangements or fusions was observed over an extended follow-up period, including a 37% ORR, a median DOR of 9.1 months, and a median PFS and OS of 7.0 and 17.5 months, respectively.